Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).

被引：3

作者：

Derman, Benjamin Avi

Zonder, Jeffrey A.

Kansagra, Ankit J.

Grinblatt, David L.

Narula, Sunil

Rayani, Shayan

Stefka, Andrew T.

Jiang, Ken

Major, Sarah

Wolfe, Brittany

Whelan, Megan

Libao, Bernadette

McIver, Amanda

Andreatos, Evangelia

Juergens, Daniel

Alcantar, Luis

Karrison, Theodore

Bishop, Michael Russell

Jasielec, Jagoda

Jakubowiak, Andrzej J.

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Malignant Hematol, Detroit, MI USA

[3] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[4] NorthShore Univ Hlth Syst, Evanston, IL USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.8011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8011

引用

页数：3